Pmv Pharmaceuticals, Inc. ( (PMVP) ) has released its Q3 earnings. Here is a breakdown of the information Pmv Pharmaceuticals, Inc. presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
PMV Pharmaceuticals, Inc. is a precision oncology company focused on developing small molecule therapies targeting p53 mutations, headquartered in Princeton, New Jersey. In its latest earnings report for the quarter ended September 30, 2025, PMV Pharmaceuticals reported a net loss of $21.1 million, compared to a net loss of $19.2 million in the same period last year. The company’s total operating expenses increased to $22.5 million, driven by higher research and development costs. Despite the losses, PMV Pharmaceuticals maintains a strong cash position with $129.3 million in cash, cash equivalents, and marketable securities, providing a runway for continued operations. Looking ahead, PMV Pharmaceuticals plans to focus on advancing its product candidates through clinical trials, with the management expressing confidence in their strategic plans and financial position to support ongoing research and development activities.